dc.contributor.author
Ambrosioni, Juan
dc.contributor.author
Sued, Omar
dc.contributor.author
Nicolás, David
dc.contributor.author
Parera, Marta
dc.contributor.author
López-Diéguez, María
dc.contributor.author
Romero, Anabel
dc.contributor.author
Agüero Santangelo, Fernando
dc.contributor.author
Marcos, Ma. Angeles
dc.contributor.author
Manzardo, Christian
dc.contributor.author
Zamora, Laura
dc.contributor.author
Gómez-Carrillo, Manuel
dc.contributor.author
Gatell, José M.
dc.contributor.author
Pumarola Suñé, Tomàs
dc.contributor.author
Miró Meda, José M. (José María), 1956-
dc.date.issued
2016-02-03T14:05:59Z
dc.date.issued
2016-02-03T14:05:59Z
dc.date.issued
2015-06-03
dc.date.issued
2016-02-02T15:34:03Z
dc.identifier
https://hdl.handle.net/2445/69204
dc.description.abstract
OBJECTIVES: To evaluate the prevalence of transmitted drug
resistance (TDR) and non-B subtypes in patients with
acute/recent HIV-1 infection in Barcelona during the period
1997-2012. METHODS: Patients from the "Hospital Clinic Primary
HIV-1 Infection Cohort" with a genotyping test performed within
180 days of infection were included. The 2009 WHO List of
Mutations for Surveillance of Transmitted HIV-1 Drug Resistance
was used for estimating the prevalence of TDR and phylogenetic
analysis for subtype determination. RESULTS: 189 patients with
acute/recent HIV-1 infection were analyzed in 4 time periods
(1997-2000, n=28; 2001-4, n=42; 2005-8, n=55 and 2009-12, n=64).
The proportion of patients with acute/recent HIV-1 infection
with respect to the total of newly HIV-diagnosed patients in our
center increased over the time and was 2.18%, 3.82%, 4.15% and
4.55% for the 4 periods, respectively (p=0.005). The global
prevalence of TDR was 9%, or 17.9%, 9.5%, 3.6% and 9.4% by study
period (p=0.2). The increase in the last period was driven by
protease-inhibitor and
nucleoside-reverse-transcriptase-inhibitor resistance mutations
while non-nucleoside-reverse-transcriptase inhibitor TDR and TDR
of more than one family decreased. The overall prevalence of
non-B subtypes was 11.1%, or 0%, 4.8%, 9.1% and 20.3 by study
period (p=0.01). B/F recombinants, B/G recombinants and subtype
F emerged in the last period. We also noticed an increase in the
number of immigrant patients (p=0.052). The proportion of
men-who-have-sex-with-men (MSM) among patients with acute/recent
HIV-1 infection increased over the time (p=0.04). CONCLUSIONS:
The overall prevalence of TDR in patients with acute/recent
HIV-1 infection in Barcelona was 9%, and it has stayed
relatively stable in recent years. Non-B subtypes and immigrants
proportions progressively increased.
dc.format
application/pdf
dc.publisher
Public Library of Science (PLoS)
dc.relation
Reproducció del document publicat a:
http://dx.doi.org/10.1371/journal.pone.0125837
dc.relation
PLoS One, 2015, vol. 10, num. 6, p. e0125837
dc.relation
http://dx.doi.org/10.1371/journal.pone.0125837
dc.rights
cc by (c) Ambrosioni et al., 2015
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (ISGlobal)
dc.subject
Persones seropositives
dc.subject
Resistència als medicaments
dc.subject
Assaigs clínics
dc.subject
Barcelona (Catalunya)
dc.subject
HIV-positive persons
dc.subject
Drug resistance
dc.subject
Clinical trials
dc.subject
Barcelona (Catalonia)
dc.title
Trends in Transmission of Drug Resistance and Prevalence of
Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection
in Barcelona in the Last 16 Years (1997-2012)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion